The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors: clinical outcomes and medical encounters from the patient perspective

ABSTRACT Objectives: To assess the clinical and healthcare resource burden among C5 inhibitor (C5i)-treated patients with paroxysmal nocturnal haemoglobinuria (PNH), using patient-reported data. Methods: This web-based, cross-sectional survey (01FEB2021–31MAR2021) of adults with PNH treated with eculizumab (France, Germany, UK) or ravulizumab (Germany) included: patient characteristics; treatment patterns/dosage; haematological outcomes (haemoglobin [Hb] levels, transfusions, thrombotic events, breakthrough haemolysis); and medical encounters. Treatment and Hb-level subgroup differences were assessed with statistical significance tests. Results: Among 71 patients, 98.6% were C5i-treated for ≥3 months. The majority (with reported Hb levels) had levels ≤12.0 g/dL (85.7%; n = 54/63). The mean Hb level was 10.2 g/dL (standard deviation [SD]: 2.0; median 10.0 g/dL). Treatment with above label-recommended doses was reported by 30.4% (eculizumab) and 5.3% (ravulizumab) of patients. Within the past 12 months among patients treated with C5i for ≥1 year: 24.1% had ≥1 transfusion; 3.2% had ≥1 thrombosis; and 28.6% had ≥1 breakthrough haemolysis. Among all patients, 26.8% and 31.0% reported emergency department/room [ER] and inpatient visits, respectively. Mean annual, per-patient all-cause medical encounters were: 0.5 (ER); 1.9 (inpatient); and overall outpatient visits ranged by setting from 2.0 to 6.4. Most encounters were PNH-related, with means of 0.4 (ER); 1.8 (inpatient); and 1.6–5.4 (outpatient). Primary haematological and medical encounter outcomes were similar between treatment as well as Hb-level subgroups, with almost no statistically significant differences. Conclusions: Despite at least 3 months of C5i treatment, high proportions of patients with PNH reported low haemoglobin levels and required transfusions and hospitalizations, which suggests remaining unmet needs.

[1]  J. E. Matos,et al.  The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: Patient‐reported insights on symptoms and quality of life , 2022, European journal of haematology.

[2]  J. E. Matos,et al.  The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey , 2022, Annals of Hematology.

[3]  S. Krishnan,et al.  Real-World Eculizumab Dosing Patterns Among Patients with Paroxysmal Nocturnal Hemoglobinuria in a US Population , 2020, ClinicoEconomics and outcomes research : CEOR.

[4]  D. Cella,et al.  Clinically Important Difference for the FACIT-Fatigue Scale in Paroxysmal Nocturnal Hemoglobinuria: A Derivation from International PNH Registry Patient Data , 2021, Blood.

[5]  A. Bogdanović,et al.  COVID-19 Presented with Deep Vein Thrombosis in a Patient with Paroxysmal Nocturnal Haemoglobinuria , 2021, Hämostaseologie.

[6]  A. Risitano,et al.  How we(’ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future , 2021, British journal of haematology.

[7]  S. Krishnan,et al.  Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population , 2021, Advances in Therapy.

[8]  Shruti Chaturvedi,et al.  COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria , 2021, Blood.

[9]  C. Sherbourne,et al.  A Consensus-Based Checklist for Reporting of Survey Studies (CROSS) , 2021, Journal of General Internal Medicine.

[10]  J. Panse,et al.  Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. , 2021, The New England journal of medicine.

[11]  J. Barrientos,et al.  COVID‐19 infection presenting as paroxysmal nocturnal hemoglobinuria , 2021, Clinical case reports.

[12]  C. Copley-Merriman,et al.  Paroxysmal nocturnal hemoglobinuria: current treatments and unmet needs , 2020, Journal of managed care & specialty pharmacy.

[13]  C. Copley-Merriman,et al.  Paroxysmal nocturnal hemoglobinuria: patient journey and burden of disease. , 2020, Journal of managed care & specialty pharmacy.

[14]  M. Lübbert,et al.  Hemolytic crisis in a patient treated with eculizumab for paroxysmal nocturnal hemoglobinuria possibly triggered by SARS-CoV-2 (COVID-19): a case report , 2020, Annals of Hematology.

[15]  J. Panse,et al.  Effect of Pegcetacoplan on Quality of Life in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Pegasus Phase 3 Trial Comparing Pegcetacoplan to Eculizumab , 2020 .

[16]  M. Griffin,et al.  A review of the treatment landscape in paroxysmal nocturnal haemoglobinuria: where are we now and where are we going? , 2020, Therapeutic advances in rare disease.

[17]  R. Wells,et al.  One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study , 2020, Therapeutic advances in hematology.

[18]  P. Muus,et al.  COVID‐19 infection in patients on anti‐complement therapy: The Leeds National Paroxysmal Nocturnal Haemoglobinuria service experience , 2020, British journal of haematology.

[19]  Scott J Johnson,et al.  Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria , 2020, PharmacoEconomics.

[20]  J. Maciejewski,et al.  Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry , 2020, Annals of Hematology.

[21]  J. Maciejewski,et al.  Characterization of breakthrough hemolysis events observed in the phase III randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria , 2020, Haematologica.

[22]  R. Brodsky,et al.  Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab , 2020, Hematology.

[23]  P. Scheinberg,et al.  Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT , 2019, Front. Immunol..

[24]  H. Schrezenmeier,et al.  Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. , 2019, Blood.

[25]  R. Wells,et al.  Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. , 2019, Blood.

[26]  G. Garcia-Manero,et al.  Fatigue, symptom burden, and health‐related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria , 2019, Cancer medicine.

[27]  D. Cella,et al.  General Population Norms for the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale. , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[28]  Stefan Schneider,et al.  The effects of time frames on self-report , 2018, PloS one.

[29]  S. Meri,et al.  Spontaneous Remission in Paroxysmal Nocturnal Hemoglobinuria—Return to Health or Transition Into Malignancy? , 2018, Front. Immunol..

[30]  S. Richards,et al.  Extravascular Hemolysis Due to C3-Loading in Patients with PNH Treated with Eculizumab: Defining the Clinical Syndrome , 2017 .

[31]  T. Kinoshita,et al.  Paroxysmal nocturnal haemoglobinuria , 2017, Nature Reviews Disease Primers.

[32]  Alaa M Althubaiti,et al.  Information bias in health research: definition, pitfalls, and adjustment methods , 2016, Journal of multidisciplinary healthcare.

[33]  J. Dogné,et al.  Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: a review , 2015, European journal of haematology.

[34]  R. Brodsky,et al.  Paroxysmal nocturnal hemoglobinuria. , 2014, Blood.

[35]  A. Hinz,et al.  European reference values for the quality of life questionnaire EORTC QLQ-C30: Results of a German investigation and a summarizing analysis of six European general population normative studies , 2014, Acta oncologica.

[36]  J. Maciejewski,et al.  Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry , 2014, Haematologica.

[37]  P. Hillmen,et al.  Thrombosis in paroxysmal nocturnal hemoglobinuria. , 2013, Blood.

[38]  A. Risitano.  Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies. , 2013, Advances in experimental medicine and biology.

[39]  W. Gregory,et al.  Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. , 2010, Blood.

[40]  R. Brodsky.  Stem cell transplantation for paroxysmal nocturnal hemoglobinuria , 2010, Haematologica.

[41]  S. Richards,et al.  Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization , 2010, Haematologica.

[42]  A. Zanella,et al.  Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. , 2009, Blood.

[43]  S. Richards,et al.  Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. , 2004, The New England journal of medicine.

[44]  S M Lewis,et al.  Natural history of paroxysmal nocturnal hemoglobinuria. , 1995, The New England journal of medicine.

[45]  P. Vossough.  Chronic anemia. , 1973, Clinical pediatrics.